Loading...
XNAS
CMND
Market cap2mUSD
Jul 10, Last price  
2.03USD
1D
-1.43%
1Q
-83.83%
IPO
-99.98%
Name

Clearmind Medicine Inc

Chart & Performance

D1W1MN
XNAS:CMND chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
208.72%
Rev. gr., 5y
%
Revenues
0k
Net income
-4m
L-26.61%
-6,529-198,094-104,148-230,119-3,655,980-9,928,520-8,609,081-5,254,671-3,856,627
CFO
-5m
L-30.00%
-8,929-80,479-47,851-198,501-2,077,096-5,055,276-6,301,472-6,763,253-4,734,061

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
IPO date
May 15, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT